ClinicalTrials.gg
RecruitingNCT04625023METAMECHUpdated May 1, 2025

A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer

An observational study in Breast Cancer, sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology. Recruiting at 10 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by IFOM ETS - The AIRC Institute of Molecular Oncology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 887 studies in Breast Neoplasms with a site in Italy — 231 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.

Planned enrollment
23rd of 195
1,500 · median 256
Started
2020
with 43 others
Observational
196 of 887
103 open now
Primary completion
2026-07
later than 149 of 349 live
Registered
517th of 887
by date

Among the 887 studies in Breast Neoplasms with a site in Italy, this one is the 23rd largest by planned enrollment of the 195 observational ones that give a count, is one of 44 that started in 2020, is one of 196 observational ones, reaches primary completion later than 149 of the 349 other live ones, and was the 517th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

231 of the 887 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

226 more — sign in →

All 231 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 887 studies in Breast Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

METAMECH is a master observational protocol designed to empower a bi-directional collaboration between basic and clinical research, an essential prerequisite to feed and implement precision oncology.

METAMECH will follow a stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years. Patients will be longitudinally sampled and matched clinical data (including imaging) will be collected. Via a multi-tiered informed consensus process, METAMECH will also allow to develop companion diagnostics for molecular enrichment strategies in AIRC-driven proof-of-concept trials.

Read the detailed description

METAMECH has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of breast cancer (BC) patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improve). This clinical resource for integrative clinical data and sample collection will allow to generate hypotheses on mechanisms supporting the outgrowth of human metastases, mine for new potentially actionable targets and the selection of appropriate patients for experimentally-driven trials. To achieve the required level of 'experimental precision', patients will enter METAMECH at two different 'therapeutic checkpoints': i) prior to a tumor sampling event (surgery, biopsy) or ii) prior to any line of treatment.

To optimize the enrollment of patients, the longitudinal collection of data/samples and their logistic management, METAMECH has been designed as a flexible infrastructure organized in Tiers for the stepwise comprehension of the biological processes that drive tumor evolution, and precisely:

  • TIER0, Retrieving: the ability to retrospectively retrieve clinically annotated BC archival samples to validate/discover new mechanotransduction-linked biomarkers;
  • TIER1, Recording: the ability to prospectively record BC characteristics under standard of care treatments and to define new mechanotransduction-linked biomarkers;
  • TIER2, Modelling: the ability to develop pertinent experimental models to study the aberrant mechanisms underlying the metastatic outgrowth and define mechanotransduction-targeting therapeutic strategies;
  • TIER3, Linking: the ability to access data and samples of patients enrolled in POC trials to prove the efficacy and study/understand resistance mechanisms of mechanotransduction-targeting therapies.
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Stage-mixed Breast Cancer (BC) patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Verification that the patient could not be reached for in accordance with applicable national regulations or, alternatively, TIER1 written Informed consent.
  2. Patients ≥18 years of age.
  3. Previous diagnosis of breast cancer, or a strong suspicion of BC based on clinical and radiological findings.
  4. Performance status \< 2 (only for TIER1-2).

Exclusion criteria

Exclusion Criteria:

  1. Any other current or malignancy diagnosed or within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer)
  2. Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.
  3. Known (HIV), Virus (HBV), Virus (HCV) or syphilis infection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort of BC patients

    Stage-mixed cohort of at least 1500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.

    Other: Observational

Interventions

  • OtherObservational

    Retrospective cohorts and Prospective observation of standard clinical practice

06

What researchers measure

Primary outcomes

  1. Number of patients recruited in TIER0 and TIER 1

    Number of recruited BC cases in TIER 0 and in TIER 1 with complete clinically annotated FFPE and/or frozen biological samples

    Time frame: 6 months

  2. Number of patients recruited in TIER2

    Number of recruited BC cases in TIER 2

    Time frame: 6 months

Secondary outcomes

  1. Number of patients triaged in proof-of concept (POC) clinical trials

    Number of BC cases recruited in TIER 3

    Time frame: 6 months

Other outcomes

  1. New prognostic mechanotransduction-linked markers

    Number of identified/validated new prognostic mechanotransduction-linked markers

    Time frame: 6 months

  2. New predictive mechanotransduction-linked markers

    Number of identified/validated new predictive mechanotransduction-linked markers

    Time frame: 6 months

  3. Biomarkers correlation with RR

    Correlation between identified biomarkers with therapies response rates (RR)

    Time frame: 6 months

  4. Biomarkers correlation with PFS

    Correlation between identified biomarkers with progression-free survival (PFS)

    Time frame: 6 months

  5. Biomarkers correlation with OS

    Correlation between identified biomarkers with overall survival (OS)

    Time frame: 6 months

07

Study locations

9 of 10 sites recruiting
  • Asst Papa Giovanni Xxiii
    Bergamo, Bergamo 24127, Italy
    Not yet recruiting
    • Vittoria Fotia, MD · Principal investigator
  • Fondazione IRCCS, Istituto Nazionale dei Tumori
    Milan, Milan 20133, Italy
    Recruiting
    • Filippo De Braud, MD · Principal investigator
  • Fondazione IRCCS, Istituto Neurologico Carlo Besta
    Milan, Milan 20133, Italy
    Recruiting
    • Cecilia Casali, MD · Principal investigator
  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
    Novara, Novara 28100, Italy
    Recruiting
    • Alessandra Gennari, MD · Principal investigator
  • Istituto Oncologico Veneto IRCCS (IOV)
    Padova, Padova 35128, Italy
    Recruiting
    • Valentina Guarneri, MD · Principal investigator
  • Fondazione IRCCS, Policlinico San Matteo Pavia
    Pavia, Pavia 27100, Italy
    Recruiting
    • Paolo Pedrazzoli, MD · Principal investigator
  • Istituto Nazionale Tumori Regina Elena di Roma - Istituti Fisioterapici Ospitalieri (IFO)
    Roma, Roma 00144, Italy
    Recruiting
    • Giovanni Blandino, MD · Principal investigator
  • IRCCS Humanitas
    Milan, 20089, Italy
    Recruiting
    • Alberto Zambelli, MD · Principal investigator
  • IEO - Istituto Europeo di Oncologia
    Milan, 20141, Italy
    Recruiting
    • Viviana Galimberti · Principal investigator
  • Azienda U.S.L. - IRCCS di Reggio Emilia
    Reggio Emilia, 42122, Italy
    Recruiting
    • Filippo Giovanardi, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jul 2026, 72 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 72 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 12, 2020
StartActual
Jul 16, 2020
Primary completionEst.
Jul 2026
CompletionEst.
Dec 2026
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04625023
Lead sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Jul 16, 2020
Primary completion
Jul 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 1, 2025

Study contacts

Smeralda Rapisarda
Contact
clinical.trials@ifom.eu
+3902574303236
Ylenia Silvestri, PhD
Contact
clinical.trials@ifom.eu
+3902574303799
Silvia Marsoni, MD
study chair · IFOM ETS - The AIRC Institute of Molecular Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion